Back to search results

Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell Transplant

Abroad (travel likely)RecruitingPHASE1

Conditions

Acute Myeloid Leukemia

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States

    Contact: Study coordinator (Amer Beitinjaneh, MD) · abeitinjaneh@miami.edu · 305-243-9127
    Contact: Study coordinator (Alessandro Perinuzz) · amp452@med.miami.edu · 630-741-4990
    Contact: Principal Investigator (Amer Beitinjaneh, MD)

  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States

    Contact: Study coordinator (Tara Haney, RN) · tnhaney@iu.edu · 317-278-4184
    Contact: Study coordinator (Huda Salman, MD, PhD) · hsalman@iu.edu · 317-278-9504

  • Riley Hospital for Children, Indianapolis, Indiana, United States

    Contact: Study coordinator (Courtney Spiegel, BS) · clorch@iu.edu · (317) 278-3105
    Contact: Principal Investigator (Jodi Skiles, MD)

  • The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

    Contact: Study coordinator (Brianna Kammerer, RN) · bekammerer@mdanderson.org · 832-270-9423
    Contact: Principal Investigator (Nicholas Short, MD)
Study leads

  • Huda Salman, MD, PhD

    Principal Investigator

    Indiana University

View source on ClinicalTrials.gov(opens in a new tab)